But it's a compelling signal that gut bacteria and GLP-1 therapy may be complementary rather than redundant
In SOUL, composite HF endpoints were analysed as a secondary outcome, with oral semaglutide resulting in a non-significant reduction in HF events

Each receptor contributes distinct effects: GLP-1 Receptor Component Glucose-dependent insulin secretion from pancreatic beta cells Glucagon suppression in pancreatic alpha cells Slowed gastric emptying Hypothalamic appetite reduction GIP Receptor Component Additional insulin secretion enhancement (synergistic with GLP-1) Direct adipose tissue effects on lipid metabolism Centrally mediated appetite effects via brain GIP receptors Glucagon Receptor Component (Unique to Retatrutide) Increased energy expenditure glucagon receptor activity raises metabolic rate Hepatic glucose output modulation increases glucose production in liver (counterbalanced by GLP-1s insulin effects) Direct fatty acid oxidation effects in liver and muscle tissue Body composition effects from energy expenditure changes The glucagon receptor component is what makes retatrutide unique
That timeline gives context to the urgency of having a post-treatment plan
Kumar, Berberine shows data for improved glucose metabolism, so its something that could be considered more of a natural Metformin, but [it does have] he level of clinical efficacy of a GLP-1. Metformin is another prescription medication sometimes prescribed for weight loss
NAD+ precursor NMN is not authorised for sale as a food supplement in Great Britain